Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

(2014) Rebecca Rawlinson et al.   BMC CANCER

Chk1 as a new therapeutic target in triple-negative breast cancer

(2014) Laurence Albiges et al.   BREAST

Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells

(2014) Christopher Bryant et al.   Molecular Cancer

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

(2013) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes

(2013) Enilze Ribeiro et al.   PLoS One

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

(2012) Wanjuan Yang et al.   NUCLEIC ACIDS RESEARCH

A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress

(2012) K Brooks et al.   ONCOGENE

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition

(2011) Hidetaka Shibata et al.   CANCER SCIENCE

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

(2011) T. J. Guzi et al.   MOLECULAR CANCER THERAPEUTICS

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

(2011) Kurtis D. Davies et al.   ONCOLOGY RESEARCH

Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation

(2011) Josep V. Forment et al.   PLoS One

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

(2011) K. A. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells

(2011) Elizabeth Alli et al.   BMC Pharmacology & Toxicology

Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo

(2010) Zizhen Feng et al.   CANCER LETTERS

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin

(2010) K. Hastak et al.   CANCER RESEARCH

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

(2010) Ana Bosch et al.   CANCER TREATMENT REVIEWS

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Chk1 promotes replication fork progression by controlling replication initiation

(2010) E. Petermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY

DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress

(2009) V. Leung-Pineda et al.   CANCER RESEARCH

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

(2009) Clark C Chen et al.   Molecular Cancer

The F Box Protein Fbx6 Regulates Chk1 Stability and Cellular Sensitivity to Replication Stress

(2009) You-Wei Zhang et al.   MOLECULAR CELL

Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase

(2009) Zhenjian Cai et al.   MOLECULAR CELL

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS